RE:Waiting for a New York based AGP analyst to "weigh in".....Somehow I think they are comfortable with a 40% loss over 5 months...strange huh? ; - )
Their bought deal at 42.5 cents CAD done here in the US is ready for the next chapter - IMHO. Bought deals are typically done at a "discount", and given our level of FDA advancement on two fronts ( PMX and Dialco ) 42.5 CAD was a "gift". I'm waiting for the tide to turn if you will, thus far it appears more about a "ride to churn"...sounds similar but indeed so different. The Paradigm analyst is MIA as far as my CAD contacts tell me, little to NO sign of their $2.40 SP target, but a clear signal with 87.5K SOLD buy #16 just days before the 15 cent Friday Freddie Fat Finger event.
Stay tuned, as our CMO has. Whether it is Altercyte or DSMB management of the phase 3 Euphrates fiasco, he has been "around" for near a "decade". With Omicron heating up, perhaps the former CEO's ( and pioneer of the theranostic approach ) previous call ( April 2020 ) to apply any and all EDT product through to the end of the pandemic comes back into play. If the phase 2 Euphas was stopped at patient 64 of 128 ( due to a 21% 28 day mortality benefit ), and our results continue to "exceed expectations", how does the FDA message over 300, 000 RWD ( real world data ) applications of PMX when guided by the 2003 FDA approved EAA diagnostic and applied by the 2018 FDA approved SAMI hemo-device? I'm not here to play the "humanitarin card", instead I'm asking the company and the FDA where we stand from a "common cents" standpoint and I don't mean a "dirty little" 15 common cent Friday walkdown either...
BON appy...don't let any $lack form in your line, you might want to make sure this one ends up in the boat ; - ) Looks like the only "advertised" fisherman at the moment is "CAD retail" ...purrrrfect, nothing to chance and everything to CONTROL!
ALL in my humble opinion, always seek real professional opinion on matters of $100 or more